In the era of targeted therapeutics, the inadequate representation of Black populations in prostate cancer models limits effective drug screening. In this study, we introduce ACRJ-PC28, a novel Afro-Caribbean prostate cancer cell line, and evaluate its responses to five anticancer drugs (docetaxel, cabazitaxel, abiraterone, olaparib, and enzalutamide) and betaine. We compare these responses with those of established prostate cancer cell lines from Black (MDA-PCA-2b) and White (DU-145 and PC-3) donors using three distinct viability assays. We observed ancestry-dependent drug sensitivities: abiraterone showed remarkable selectivity for ACRJ-PC28 (IC50 = 1.10 μmol/L), being 4.6- to 13.1-fold more potent than in other cell lines, whereas enzalutamide demonstrated pronounced racial differences, being 3 to 5 times less effective in cell lines from Black donors (IC50 = 206 μmol/L for ACRJ-PC28; 104 μmol/L for MDA-PCA-2b) versus cell lines from White donors (IC50 = 37 μmol/L for PC-3; 48 μmol/L for DU-145). RNA sequencing analysis revealed consistent underexpression of TNF family genes, particularly TNFRSF14, in prostate cancer cells from Black donors correlating with differential drug responses. Despite underexpressing AR, the ACRJ-PC28 line exhibited exceptional sensitivity to abiraterone, consistent with clinical observations that Black patients with prostate cancer respond better to this therapy. This aligns with its neuroendocrine phenotype in the source patient, who succumbed within 1 year despite androgen deprivation therapy. Our findings suggest that incorporating diverse prostate cancer models in preclinical screening could guide personalized treatment strategies for Black patients who experience disproportionate prostate cancer mortality by identifying ancestry-specific drug vulnerabilities that inform optimal therapeutic combinations. Significance: This study introduces ACRJ-PC28, the first Afro-Caribbean prostate cancer cell line, revealing ancestry-dependent drug sensitivities that could explain differential clinical outcomes. The findings demonstrate critical gaps in current preclinical models and support incorporating diverse cell lines to develop personalized treatment strategies for underrepresented populations experiencing disproportionate cancer mortality.
In the era of targeted therapeutics, the inadequate representation of Black populations in prostate cancer models limits effective drug screening. In this study, we introduce ACRJ-PC28, a novel Afro-Caribbean prostate cancer cell line, and evaluate its responses to five anticancer drugs (docetaxel, cabazitaxel, abiraterone, olaparib, and enzalutamide) and betaine. We compare these responses with those of established prostate cancer cell lines from Black (MDA-PCA-2b) and White (DU-145 and PC-3) donors using three distinct viability assays. We observed ancestry-dependent drug sensitivities: abiraterone showed remarkable selectivity for ACRJ-PC28 (IC50 = 1.10 μmol/L), being 4.6- to 13.1-fold more potent than in other cell lines, whereas enzalutamide demonstrated pronounced racial differences, being 3 to 5 times less effective in cell lines from Black donors (IC50 = 206 μmol/L for ACRJ-PC28; 104 μmol/L for MDA-PCA-2b) versus cell lines from White donors (IC50 = 37 μmol/L for PC-3; 48 μmol/L for DU-145). RNA sequencing analysis revealed consistent underexpression of TNF family genes, particularly TNFRSF14, in prostate cancer cells from Black donors correlating with differential drug responses. Despite underexpressing AR, the ACRJ-PC28 line exhibited exceptional sensitivity to abiraterone, consistent with clinical observations that Black patients with prostate cancer respond better to this therapy. This aligns with its neuroendocrine phenotype in the source patient, who succumbed within 1 year despite androgen deprivation therapy. Our findings suggest that incorporating diverse prostate cancer models in preclinical screening could guide personalized treatment strategies for Black patients who experience disproportionate prostate cancer mortality by identifying ancestry-specific drug vulnerabilities that inform optimal therapeutic combinations.Significance:This study introduces ACRJ-PC28, the first Afro-Caribbean prostate cancer cell line, revealing ancestry-dependent drug sensitivities that could explain differential clinical outcomes. The findings demonstrate critical gaps in current preclinical models and support incorporating diverse cell lines to develop personalized treatment strategies for underrepresented populations experiencing disproportionate cancer mortality.
DEGs: Black-derived vs White-derived PCa Lines. This table documents the 633 genes differentially expressed between Black-derived (ACRJ-PC28 and MDA-PCA-2b) and White-derived (DU-145 and PC-3) PCa cell lines. The data includes gene identifiers, annotations, expression fold changes, statistical significance values, and functional pathway associations. The table highlights genes consistently underexpressed in Black-derived cell lines, including TNFRSF14 and other genes involved in androgen signaling, DNA damage repair, and growth factor pathways that may contribute to the observed ancestry-dependent differences in drug sensitivity, particularly to androgen-targeted therapies and PARP inhibitors.
DEGs in MDA-PCA-2b vs Other PCa. This supplementary table presents the 887 differentially expressed genes identified when comparing the Black-derived MDA-PCA-2b cell line against all other PCa cell lines (ACRJ-PC28, DU-145, and PC-3). The table includes gene symbols, descriptions, log2 fold changes, adjusted p-values, and functional classifications. Notable genes include overexpressed AR and underexpressed TNFRSF14 and TIPARP, along with members of growth factor families (VEGFC, FGF2, EGFLAM, HBEGF, and EGFL7) that may influence the cell line's unique response to targeted therapies, particularly its resistance to Olaparib and reduced sensitivity to Enzalutamide.
Drug concentration ranges used for cytotoxicity testing. Concentration ranges were determined based on literature review of previously published studies (19–25) for each compound. Drug concentrations are shown in the units indicated for each column header.
DEGs in ACRJ-PC28 vs Other PCa. This table presents the complete list of 1396 differentially expressed genes (DEGs) identified when comparing the novel Afro-Caribbean ACRJ-PC28 cell line against all other PCa cell lines (DU-145, PC-3, and MDA-PCA-2b). For each gene, we provide the gene symbol, gene name, log2 fold change, adjusted p-value, and functional categorization. Key genes highlighted include AR, TNFRSF14, C1QTNF9B, TNFSF11, TRAF, PARP1, BRCA1/2, RAD51, and FGFR family members, which may contribute to the unique drug response profile observed in ACRJ-PC28 cells.